BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists
ABSTRACT Biosimilars are not generic drugs. These are more complex medications than small molecules, with identical chemical structures of monoclonal antibodies that lost their patency over time. Besides identical to the original product at the end, the process of achieving its final forms differs f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
2015-03-01
|
| Series: | Arquivos de Gastroenterologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032015000100016&lng=en&tlng=en |
| _version_ | 1818291802761854976 |
|---|---|
| author | Fábio Vieira TEIXEIRA Paulo Gustavo KOTZE Aderson Omar Mourão Cintra DAMIÃO Sender Jankiel MISZPUTEN |
| author_facet | Fábio Vieira TEIXEIRA Paulo Gustavo KOTZE Aderson Omar Mourão Cintra DAMIÃO Sender Jankiel MISZPUTEN |
| author_sort | Fábio Vieira TEIXEIRA |
| collection | DOAJ |
| description | ABSTRACT Biosimilars are not generic drugs. These are more complex medications than small molecules, with identical chemical structures of monoclonal antibodies that lost their patency over time. Besides identical to the original product at the end, the process of achieving its final forms differs from the one used in the reference products. These differences in the formulation process can alter final outcomes such as safety and efficacy of the drugs. Recently, a biosimilar of Infliximab was approved in some countries, even to the management of inflammatory bowel diseases. However, this decision was based on studies performed in rheumatologic conditions such as rheumatoid arthritis and ankylosing spondylitis. Extrapolation of the indications from rheumatologic conditions was done for Crohn’s disease and ulcerative colitis based on these studies. In this article, the authors explain possible different mechanisms in the pathogenesis between rheumatologic conditions and inflammatory bowel diseases, that can lead to different actions of the medications in different diseases. The authors also alert the gastroenterological community for the problem of extrapolation of indications, and explain in full details the reasons for being care with the use of biosimilars in inflammatory bowel diseases without specific data from trials performed in this scenario. |
| first_indexed | 2024-12-13T02:49:52Z |
| format | Article |
| id | doaj.art-3aa983943c9c400ebc6efb7017732c41 |
| institution | Directory Open Access Journal |
| issn | 1678-4219 |
| language | English |
| last_indexed | 2024-12-13T02:49:52Z |
| publishDate | 2015-03-01 |
| publisher | Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) |
| record_format | Article |
| series | Arquivos de Gastroenterologia |
| spelling | doaj.art-3aa983943c9c400ebc6efb7017732c412022-12-22T00:02:05ZengInstituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)Arquivos de Gastroenterologia1678-42192015-03-01521768010.1590/S0004-28032015000100016S0004-28032015000100016BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologistsFábio Vieira TEIXEIRAPaulo Gustavo KOTZEAderson Omar Mourão Cintra DAMIÃOSender Jankiel MISZPUTENABSTRACT Biosimilars are not generic drugs. These are more complex medications than small molecules, with identical chemical structures of monoclonal antibodies that lost their patency over time. Besides identical to the original product at the end, the process of achieving its final forms differs from the one used in the reference products. These differences in the formulation process can alter final outcomes such as safety and efficacy of the drugs. Recently, a biosimilar of Infliximab was approved in some countries, even to the management of inflammatory bowel diseases. However, this decision was based on studies performed in rheumatologic conditions such as rheumatoid arthritis and ankylosing spondylitis. Extrapolation of the indications from rheumatologic conditions was done for Crohn’s disease and ulcerative colitis based on these studies. In this article, the authors explain possible different mechanisms in the pathogenesis between rheumatologic conditions and inflammatory bowel diseases, that can lead to different actions of the medications in different diseases. The authors also alert the gastroenterological community for the problem of extrapolation of indications, and explain in full details the reasons for being care with the use of biosimilars in inflammatory bowel diseases without specific data from trials performed in this scenario.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032015000100016&lng=en&tlng=enMedicamentos biossimilaresColite ulcerativaDoença de Crohn |
| spellingShingle | Fábio Vieira TEIXEIRA Paulo Gustavo KOTZE Aderson Omar Mourão Cintra DAMIÃO Sender Jankiel MISZPUTEN BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists Arquivos de Gastroenterologia Medicamentos biossimilares Colite ulcerativa Doença de Crohn |
| title | BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists |
| title_full | BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists |
| title_fullStr | BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists |
| title_full_unstemmed | BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists |
| title_short | BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists |
| title_sort | biosimilars in inflammatory bowel diseases an important moment for brazilian gastroenterologists |
| topic | Medicamentos biossimilares Colite ulcerativa Doença de Crohn |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032015000100016&lng=en&tlng=en |
| work_keys_str_mv | AT fabiovieirateixeira biosimilarsininflammatoryboweldiseasesanimportantmomentforbraziliangastroenterologists AT paulogustavokotze biosimilarsininflammatoryboweldiseasesanimportantmomentforbraziliangastroenterologists AT adersonomarmouraocintradamiao biosimilarsininflammatoryboweldiseasesanimportantmomentforbraziliangastroenterologists AT senderjankielmiszputen biosimilarsininflammatoryboweldiseasesanimportantmomentforbraziliangastroenterologists |